첫 페이지 News 본문

On Thursday Eastern Time, the US Food and Drug Administration (FDA) announced that the best-selling weight loss drug Zepbound from Eli Lilly is no longer in short supply, which will have a serious impact on the multi billion dollar compound medicine market. After the news was released, American telemedicine company Hims& Hers Health's stock price plummeted by over 10%.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

fafacatlin 新手上路
  • Follow

    0

  • Following

    0

  • Articles

    0